The website of the Clinical Services Journal

AI could create better outcomes for bowel cancer patients

A test which uses artificial intelligence (AI) to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment, according to new research.

A team at the University of Leeds collaborated with researchers at Roche Diagnostics to develop the technique, which will help doctors and patients to decide on the best treatment options.

They used samples from a previous trial funded by Cancer Research UK to look at the levels of two proteins, known as AREG and EREG, which are produced by some colorectal cancers.

Algorithms driven by AI enabled the researchers to show that patients with higher levels of these proteins received significant benefit from a treatment which inhibits a different protein involved in cancer cell growth, known as EGFR. Equally important was evidence that patients with low levels of the proteins did not benefit from the treatment.

Currently, anti-EGFR treatments are only given to patients with advanced, incurable bowel cancers. The researchers hope their algorithm could be used in the future to identify patients in the earlier stages of illness who could also benefit from the drugs.

Lead author of the report, Dr Christopher Williams, from the University’s Division of Pathology and Data Analytics, said: “As more treatment options become available for advanced colorectal cancer, it is becoming increasingly difficult for patients and their doctors to choose the treatment that’s right for them. This test will help patients navigate this decision-making process more easily.” 

The study was funded by Innovate UK and Roche Diagnostics as well as Yorkshire Cancer Research. It was part of a programme of work in this field being conducted by the National Pathology Imaging Co-operative.

The report’s senior author, Kandavel Shanmugam, who is a senior director of medical innovation at Roche Diagnostics, said: “As increasing numbers of complex tests are developed to target the right cancer treatments to the right patients, developing streamlined methods for delivering test results will be essential to improve cancer care.

“By using artificial intelligence to semi-automate the test process, we anticipate it may be easier for results to be delivered to patients faster to better influence treatment decisions.”

The research, Artificial intelligence-assisted amphiregulin and epiregulin immunohistochemistry predicts panitumumab benefit in RAS wild-type metastatic colorectal cancer, is published in the journal, Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-21-0120

Upcoming Events

EBME Expo 2021

Marshall Arena, Stadium MK, Milton Keynes Stadium Way West Milton Keynes MK1 1ST
30th June - 1st July

Central Sterilising Club 60th Anniversary Annual Scientific Meeting

Crowne Plaza, Bridge Foot, Stratford-upon-Avon, CV37 6YR
4th - 5th April

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Upcoming Events

EBME Expo 2021

Marshall Arena, Stadium MK, Milton Keynes Stadium Way West Milton Keynes MK1 1ST
30th June - 1st July

Central Sterilising Club 60th Anniversary Annual Scientific Meeting

Crowne Plaza, Bridge Foot, Stratford-upon-Avon, CV37 6YR
4th - 5th April

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 10/05/2021 09:27:49 Step Communications Ltd. Registered in England. Registration Number 3893025